Venable served as patent counsel in advising international pharmaceutical company Grünenthal on its acquisition of Valinor Pharma and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Read more about this transaction here.
The Venable team is comprised of Life Sciences Patent partners David Barr, Chris Borello, and Alicia Russo, and associate Jerrit Yang.